Liège, Belgium, 18 January 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive.
Share it
Latest news
Mithra reaches milestone in estetrol skin study
8 April 2024
Mithra updates on its ongoing monetization process
28 March 2024